The Hemodynamic Response to Prolonged Dobutamine Infusion

Phase 4

• Conditions: Healthy; Heart Failure
• Interventions: Drug: 3 hours intravenous dobutamine

• Registration Number: NCT01042873
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.

Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-01-05
• Study First Submitted QC: 2010-01-05
• Study First Posted: 2010-01-06
• Status Verified: 2018-03
• Last Update Submitted: 2018-06-11
• Last Update Posted: 2018-06-12
• Primary Completion: 2020-12
• Study Completion: 2021-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• healthy subjects

Exclusion Criteria

• consumption of any medications during the 2 weeks prior to the study
• history of chest pain or tachycardia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Intravenous dobutamine	3 hours intravenous dobutamine	3 hours infusion of dobutamine

Primary Outcome Measures

Name	Time	Method
Heart rate	3 hours

Secondary Outcome Measures

Name	Time	Method
Systolic blood pressure	3 hours

Trial Locations

Locations (1)

Hadassah University Hospital; 🇮🇱 Jerusalem, Israel